A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Roche
- 04 Sep 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 05 Apr 2017 This trial has been completed in the UK (end date: 13 Oct 2016).